孟坦丁治疗改善了阿片类药物诱导的过敏症症状:随机化临床试验
Afagh Anjomshoaa1, Ahmad Zolghadriha2, Nafiseh Sadat Haj-Seyed-Taghia1
1Department of Psychiatry, Shahid Beheshti Hospital, Zanjan University of Medical Sciences, Zanjan, Iran.
Scientific reports
|December 15, 2025
概括
孟坦丁可以通过改善阿片类药物依赖患者的疼痛耐受性和减少疼痛强度来帮助管理阿片类药物诱导的过敏症 (OIH). 需要进一步的研究来证实这些关于OIH治疗的初步发现.
科学领域:
- 疼痛管理 疼痛管理
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿片类药物诱导的过敏症 (OIH) 是由于长时间使用阿片类药物而导致疼痛敏感度的悖论性增加.
- 在管理慢性疼痛和阿片类药物依赖方面,OIH存在挑战.
- 对OIH的有效治疗对于患者的福祉至关重要.
研究的目的:
- 评估孟坦丁在控制OIH症状方面的疗效.
- 评估孟坦因对OIH阿片类药物依赖患者疼痛耐受性和强度的影响.
- 提供关于孟坦因作为潜在的OIH治疗方法的初步证据.
主要方法:
- 一项随机临床试验与36名被诊断患有OIH的阿片类药物依赖患者进行.
- 参与者每天接受10毫克的孟坦丁或安慰剂.
- 测量了疼痛耐受性 (冷压测试) 和强度 (视觉模拟尺度).
主要成果:
- 记忆素组在2周和4周显著增加了寒冷疼痛耐受性 (p<0.005).
- 记忆剂组在2周后观察到疼痛强度显著降低 (p=0.001).
- 虽然受试者内部的影响是显著的,但群体间的影响不是显著的,这表明需要进一步研究.
结论:
- 初步发现表明,每天10毫克的美曼丁可以缓解OIH症状.
- 孟坦丁显示出改善OIH患者疼痛结果的潜力.
- 需要进一步的研究来证实孟坦因在OIH治疗中的有效性.
相关概念视频
Analgesia and Pain Management
1.4K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.4K
Opioid Analgesics: Synthetic and Semisynthetic Opioids
878
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
878
Alzheimer's Disease: Treatment
752
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
752


